Skip to content

Study · Animal study (in vivo) · mouse · 2025

7 results

Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.

Engel MG, Narayan S, Cui MH, Branch CA, Zhang X, Gandy SE, Ehrlich M, Huffman DM

Journal of Alzheimer's disease : JAD29 Nov 2024Cited by 6 (Europe PMC)

PMID39610283 (opens in a new tab)PMCIDPMC12617435 (opens in a new tab)DOI10.1177/13872877241299056 (opens in a new tab)PepBankPUB-39610283
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male 5XFAD mice, intranasal LR3-IGF-1 improved body composition versus vehicle.

    In plain wordsIn male mice bred to model Alzheimer's disease, nose-delivered LR3-IGF-1 improved body composition compared with vehicle.

    Peptide
    IGF-1 LR3
    Outcome
    Direction not reportedBody composition
    Study

    mousen: not reported in source

    5XFAD mice
    Comparator
    Vehicle
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · intranasal · 7 monthsAs given in this study (mouse).

    Source sentences

    Summary
    IN LR3-IGF-1 treatment improved body composition, but did not significantly alter cognitive symptoms, as assessed by multiple assays.
    1 context sentence
    Summary · context
    Wildtype and 5XFAD male mice were treated for 7 months (3-10 months of age), with IN LR3-IGF-1 or IN Vehicle (Veh) (n = 19-27 mice/group).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male 5XFAD mice, intranasal LR3-IGF-1 did not significantly alter cognitive symptoms in multiple assays.

    In plain wordsIn male mice bred to model Alzheimer's disease, nose-delivered LR3-IGF-1 did not clearly change memory or behavior tests compared with vehicle.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeCognitive symptoms (multiple assays)
    Study

    mousen: not reported in source

    5XFAD mice
    Comparator
    Vehicle
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 7 monthsAs given in this study (mouse).

    Source sentences

    Summary
    but did not significantly alter cognitive symptoms, as assessed by multiple assays.
    1 context sentence
    Summary · context
    Wildtype and 5XFAD male mice were treated for 7 months (3-10 months of age), with IN LR3-IGF-1 or IN Vehicle (Veh) (n = 19-27 mice/group).
  3. 03AnimalAnimal study (in vivo)Mechanism

    In male 5XFAD mice, LR3 treatment reduced filamentous plaques in cortex.

    In plain wordsIn male mice bred to model Alzheimer's disease, LR3 reduced one type of amyloid plaque in the cortex compared with vehicle.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseFilamentous plaques in cortex
    Study

    mousen: not reported in source

    5XFAD mice
    Comparator
    Vehicle
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 7 monthsAs given in this study (mouse).

    Source sentences

    Summary
    including a reduction in filamentous plaques, and increase in inert plaques, corresponding with a reduction in low molecular weight Aβ oligomers.
    1 context sentence
    Summary · context
    Wildtype and 5XFAD male mice were treated for 7 months (3-10 months of age), with IN LR3-IGF-1 or IN Vehicle (Veh) (n = 19-27 mice/group).
  4. 04AnimalAnimal study (in vivo)Mechanism

    In male 5XFAD mice, LR3 treatment increased inert plaques in cortex.

    In plain wordsIn male mice bred to model Alzheimer's disease, LR3 increased inert amyloid plaques in the cortex compared with vehicle.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseInert plaques in cortex
    Study

    mousen: not reported in source

    5XFAD mice
    Comparator
    Vehicle
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 7 monthsAs given in this study (mouse).

    Source sentences

    Summary
    and increase in inert plaques, corresponding with a reduction in low molecular weight Aβ oligomers.
    1 context sentence
    Summary · context
    Wildtype and 5XFAD male mice were treated for 7 months (3-10 months of age), with IN LR3-IGF-1 or IN Vehicle (Veh) (n = 19-27 mice/group).
  5. 05AnimalAnimal study (in vivo)Mechanism

    In male 5XFAD mice, LR3 treatment was linked to a reduction in low molecular weight Aβ oligomers in cortex.

    In plain wordsIn male mice bred to model Alzheimer's disease, LR3 lowered small amyloid-beta clusters in the cortex compared with vehicle.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseLow molecular weight Aβ oligomers in cortex
    Study

    mousen: not reported in source

    5XFAD mice
    Comparator
    Vehicle
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 7 monthsAs given in this study (mouse).

    Source sentences

    Summary
    corresponding with a reduction in low molecular weight Aβ oligomers.
    1 context sentence
    Summary · context
    Wildtype and 5XFAD male mice were treated for 7 months (3-10 months of age), with IN LR3-IGF-1 or IN Vehicle (Veh) (n = 19-27 mice/group).
  6. 06LabIn vitro (cells)Mechanism

    In BV2 microglial cells, LR3-IGF-1 enhanced uptake of the Aβ1-42 peptide.

    In plain wordsIn cells, LR3-IGF-1 increased how much amyloid-beta peptide microglial cells took up.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseAβ1-42 uptake by BV2 cells
    Study

    n: not reported in source

    BV-2 microglial cells
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    uptake of Aβ1-42 peptide by BV2 cells was enhanced by LR3-IGF-1, which was also found to promote gene pathways implicated in actin remodeling and endocytosis.
    1 context sentence
    Summary · context
    A comprehensive amyloid-β (Aβ) profile and other pathologic features were conducted and supportive in vitro stimulation studies in BV-2 microglial cells were also performed.
  7. 07LabIn vitro (cells)Mechanism

    In BV2 microglial cells, LR3-IGF-1 promoted gene pathways implicated in actin remodeling and endocytosis.

    In plain wordsIn cells, LR3-IGF-1 increased activity of genes linked to cell structure remodeling and uptake.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseActin remodeling and endocytosis gene pathways
    Study

    n: not reported in source

    BV-2 microglial cells
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    which was also found to promote gene pathways implicated in actin remodeling and endocytosis.
    1 context sentence
    Summary · context
    A comprehensive amyloid-β (Aβ) profile and other pathologic features were conducted and supportive in vitro stimulation studies in BV-2 microglial cells were also performed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.